How is iv dopamine administered

Chlorpheniramine; Dextromethorphan; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Chlorpheniramine; Dihydrocodeine; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity.

Chlorpheniramine; Guaifenesin; Hydrocodone; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity.

Chlorpheniramine; Hydrocodone; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Chlorpheniramine; Ibuprofen; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Chlorpheniramine; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity.

Chlorpromazine: Moderate The vasoconstrictive properties of dopamine infusion can be decreased due to the alpha-adrenergic blocking capability of phenothiazines. Chlorthalidone: Moderate Sympathomimetics can antagonize the effects of antihypertensives such as metolazone when administered concomitantly. Chlorthalidone; Clonidine: Major Sympathomimetics, such as dopamine, can antagonize the antihypertensive effects of clonidine when administered concomitantly.

Patients should be monitored for loss of blood pressure control. Moderate Sympathomimetics can antagonize the effects of antihypertensives such as metolazone when administered concomitantly. Clonidine: Major Sympathomimetics, such as dopamine, can antagonize the antihypertensive effects of clonidine when administered concomitantly.

Cocaine: Major Avoid concomitant use of additional vasoconstrictor agents with cocaine. If unavoidable, prolonged vital sign and ECG monitoring may be required. Myocardial ischemia, myocardial infarction, and ventricular arrhythmias have been reported after concomitant administration of topical intranasal cocaine and vasoconstrictor agents during nasal and sinus surgery. The risk for nervousness, irritability, convulsions, and other cardiac arrhythmias may increase during coadministration.

Codeine; Guaifenesin; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Colchicine: Minor The response to sympathomimetics may be enhanced by colchicine. Dapagliflozin: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically.

Dapagliflozin; Metformin: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically.

Dapagliflozin; Saxagliptin: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically. Desloratadine; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Desmopressin: Moderate Although the pressor activity of desmopressin is very low compared to its antidiuretic activity, large doses of desmopressin should be used with other pressor agents like dopamine only with careful patient monitoring.

Dexbrompheniramine; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Dexchlorpheniramine; Dextromethorphan; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Dextromethorphan; Guaifenesin; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity.

Diethylpropion: Major Diethylpropion has vasopressor effects. Coadministration with other vasopressors may have the potential for serious cardiac adverse effects such as hypertensive crisis and cardiac arrhythmias. Digitoxin: Major Concomitant use of cardiac glycosides with sympathomimetics can cause arrhythmias because sympathomimetics enhance ectopic pacemaker activity.

Digoxin: Major Concomitant use of cardiac glycosides with sympathomimetics can cause arrhythmias because sympathomimetics enhance ectopic pacemaker activity. Dihydrocodeine; Guaifenesin; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Dihydroergotamine: Major Avoid concomitant use of ergot alkaloids and vasopressors due to synergistic vasoconstriction and severe hypertension.

Dipeptidyl Peptidase-4 Inhibitors: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically.

Dorzolamide; Timolol: Minor Close monitoring of blood pressure or the selection of alternative therapeutic agents to the sympathomimetic agent may be needed in patients receiving a beta-blocker. Dronabinol: Moderate Concurrent use of dronabinol, THC with sympathomimetics may result in additive hypertension, tachycardia, and possibly cardiotoxicity. Dronabinol, THC has been associated with occasional hypotension, hypertension, syncope, and tachycardia. In a study of 7 adult males, combinations of IV cocaine and smoked marijuana, 1 g marijuana cigarette, 0 to 2.

Dulaglutide: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically. Dyphylline: Moderate Use of sympathomimetics with dyphylline should be approached with caution. Coadministration may lead to adverse effects, such as tremors, insomnia, seizures, or cardiac arrhythmias. Dyphylline; Guaifenesin: Moderate Use of sympathomimetics with dyphylline should be approached with caution.

Empagliflozin: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically.

Empagliflozin; Linagliptin: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically. Empagliflozin; Linagliptin; Metformin: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically. Empagliflozin; Metformin: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically.

Enalapril; Hydrochlorothiazide, HCTZ: Moderate Sympathomimetics can antagonize the effects of antihypertensives such as metolazone when administered concomitantly. Enflurane: Major Enflurane can sensitize the myocardium to the effects of sympathomimetics, which can increase the risk of developing cardiac arrhythmias and hypotension. Use of enflurane with a sympathomimetic should be approached with caution. Ephedrine: Moderate Nicotine use may potentiate the effects of the adrenergic agonists and the ergot alkaloids.

If significant changes in nicotine intake occur, the dosages of these drugs may need adjustment. Ephedrine; Guaifenesin: Moderate Nicotine use may potentiate the effects of the adrenergic agonists and the ergot alkaloids.

Epoprostenol: Major Avoid use of sympathomimetic agents with epoprostenol. Sympathomimetics counteract the medications used to stabilize pulmonary hypertension, including epoprostenol. Eprosartan; Hydrochlorothiazide, HCTZ: Moderate Sympathomimetics can antagonize the effects of antihypertensives such as metolazone when administered concomitantly. Ergoloid Mesylates: Major Avoid concomitant use of ergot alkaloids and vasopressors due to synergistic vasoconstriction and severe hypertension.

Ergonovine: Major Avoid concomitant use of ergot alkaloids and vasopressors due to synergistic vasoconstriction and severe hypertension. Ergot alkaloids: Major Avoid concomitant use of ergot alkaloids and vasopressors due to synergistic vasoconstriction and severe hypertension. Ergotamine: Major Avoid concomitant use of ergot alkaloids and vasopressors due to synergistic vasoconstriction and severe hypertension. Ergotamine; Caffeine: Major Avoid concomitant use of ergot alkaloids and vasopressors due to synergistic vasoconstriction and severe hypertension.

Moderate Caffeine is a CNS-stimulant and such actions are expected to be additive when coadministered with other CNS stimulants or psychostimulants. Ertugliflozin: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically. Ertugliflozin; Metformin: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically.

Ertugliflozin; Sitagliptin: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically. Esmolol: Minor Close monitoring of blood pressure or the selection of alternative therapeutic agents to the sympathomimetic agent may be needed in patients receiving a beta-blocker. Exenatide: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically.

Fexofenadine; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Fluphenazine: Moderate The vasoconstrictive properties of dopamine infusion can be decreased due to the alpha-adrenergic blocking capability of phenothiazines. Fluticasone; Salmeterol: Moderate Caution and close observation should also be used when salmeterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.

Fluticasone; Umeclidinium; Vilanterol: Moderate Administer sympathomimetics with caution with beta-agonists such as vilanterol. The cardiovascular effects of beta-2 agonists may be potentiated by concomitant use.

Monitor the patient for tremors, nervousness, increased heart rate, or other additive side effects. Fluticasone; Vilanterol: Moderate Administer sympathomimetics with caution with beta-agonists such as vilanterol.

Formoterol: Moderate Caution and close observation should be used when formoterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.

Formoterol; Mometasone: Moderate Caution and close observation should be used when formoterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects. Fosinopril; Hydrochlorothiazide, HCTZ: Moderate Sympathomimetics can antagonize the effects of antihypertensives such as metolazone when administered concomitantly.

Ginger, Zingiber officinale: Minor In vitro studies have demonstrated the positive inotropic effects of certain gingerol constituents of ginger; but it is unclear if whole ginger root exhibits these effects clinically in humans. It is theoretically possible that excessive doses of ginger could affect the action of inotropes; however, no clinical data are available. Glimepiride; Rosiglitazone: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically.

Glycopyrrolate; Formoterol: Moderate Caution and close observation should be used when formoterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects. Green Tea: Moderate Some, but not all, green tea products contain caffeine. Caffeine should be avoided or used cautiously with dopamine. CNS stimulants and sympathomimetics are associated with adverse effects such as nervousness, irritability, insomnia, and cardiac arrhythmias.

Guaifenesin; Hydrocodone; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Guaifenesin; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity.

Guanabenz: Moderate Sympathomimetics can antagonize the antihypertensive effects of guanabenz when administered concomitantly.

Haloperidol: Minor Dopamine infusions intended to improve renal perfusion can be ineffective due to haloperidol's dopamine receptor blockade. Halothane: Major Halothane can produce ventricular arrhythmias and hypertension when used concomitantly with dopamine. Hydralazine; Hydrochlorothiazide, HCTZ: Moderate Sympathomimetics can antagonize the effects of antihypertensives such as metolazone when administered concomitantly.

Hydrochlorothiazide, HCTZ: Moderate Sympathomimetics can antagonize the effects of antihypertensives such as metolazone when administered concomitantly.

Hydrochlorothiazide, HCTZ; Methyldopa: Major Sympathomimetics, such as dopamine, can antagonize the antihypertensive effects of methyldopa when administered concomitantly. Blood pressure should be monitored closely to confirm that the desired antihypertensive effect is achieved.

Hydrochlorothiazide, HCTZ; Moexipril: Moderate Sympathomimetics can antagonize the effects of antihypertensives such as metolazone when administered concomitantly. Hydrocodone; Potassium Guaiacolsulfonate; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity.

Hydrocodone; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity. Ibuprofen; Pseudoephedrine: Major Pseudoephedrine can potentiate the effects and increase the toxicity of other sympathomimetics by adding to their sympathomimetic activity.

Iloprost: Major Avoid use of sympathomimetic agents with iloprost. Sympathomimetics counteract the medications used to stabilize pulmonary hypertension, including iloprost. Incretin Mimetics: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically. Indacaterol: Moderate Administer sympathomimetics with caution with beta-agonists such as indacaterol.

Indacaterol; Glycopyrrolate: Moderate Administer sympathomimetics with caution with beta-agonists such as indacaterol. Indapamide: Moderate Sympathomimetics can antagonize the antihypertensive effects of vasodilators when administered concomitantly.

Patients should be monitored to confirm that the desired antihypertensive effect is achieved. Insulin Degludec; Liraglutide: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically.

Insulin Glargine; Lixisenatide: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically. Insulins: Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically.

Iobenguane I Major Discontinue sympathomimetics for at least 5 half-lives before the administration of the dosimetry dose or a therapeutic dose of iobenguane I Do not restart sympathomimetics until at least 7 days after each iobenguane I dose. Drugs that reduce catecholamine uptake or deplete catecholamine stores, such as sympathomimetics, may interfere with iobenguane I uptake into cells and interfere with dosimetry calculations resulting in altered iobenguane I efficacy.

Ionic Contrast Media: Major The intravascular injection of a contrast medium should never be made after the administration of vasopressors since they strongly potentiate neurologic effects. Serious neurologic sequelae, including permanent paralysis, have been reported after cerebral arteriography, selective spinal arteriography, and arteriography of vessels supplying the spinal cord.

Ipratropium; Albuterol: Major Caution and close observation should be used when albuterol is used concurrently with other adrenergic sympathomimetics, administered by any route, to avoid potential for increased cardiovascular effects.

Irbesartan; Hydrochlorothiazide, HCTZ: Moderate Sympathomimetics can antagonize the effects of antihypertensives such as metolazone when administered concomitantly.

Isocarboxazid: Contraindicated In general, sympathomimetics should be avoided in patients receiving MAOIs due to an increased risk of hypertensive crisis. This applies to sympathomimetics including stimulants for ADHD, narcolepsy or weight loss, nasal, oral, and ophthalmic decongestants and cold products, and respiratory sympathomimetics e.

Some local anesthetics also contain a sympathomimetic e. In general, medicines containing sympathomimetic agents should not be used concurrently with MAOIs or within 14 days before or after their use.

Ketamine: Moderate Closely monitor vital signs when ketamine and dopamine are coadministered; consider dose adjustment individualized to the patient's clinical situation. If this is the only available central venous line, it may be administered through the proximal injectate port but thermodilution cardiac output measurements must not be measured during infusion.

Top Stories. Getting the data on homelessness. Hospital News. Angina pectoris ; anxiety ; arrhythmias ; azotaemia ; cardiac conduction disorder ; dyspnoea ; gangrene ; headache ; hypertension ; mydriasis ; nausea ; palpitations ; piloerection ; polyuria ; tremor ; vasoconstriction ; vomiting. No evidence of harm in animal studies—manufacturer advises use only if potential benefit outweighs risk.

Dopamine concentrate for intravenous infusion to be diluted before use; give via a large vein. The mechanism of action in neonates is controversial.

Relative effects of dopamine at different doses are uncertain because of developmental differences in:. Responses tend to be individualised. Dopamine is metabolised very rapidly and is effective only when administered intravenously by continuous infusion.

The half-life of dopamine effect is 2 minutes, which is the same as the other catecholamines. No information available on protein binding. Little effect seen on heart rate or cardiac output. Increased blood flow accompanied by increased urine output. An increase in cardiac contractility and cardiac output results in increased normal blood flow and heart rate. Decrease in normal perfusion. Dosage range is determined by type of desired clinical effect.

Start at the lower end of the desired range and titrate according to clinical response. Use with caution in patients with persistent pulmonary hypertension of the newborn. The usual amount needed is ml, depending on the size of the infiltrate. General anaesthetic: increased risk of arrhythmias or hypertension. Phenytoin may lower blood pressure.